Diffuse large B-cell lymphoma: open trials in Colombia

• NCT05139017

  A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

  Trial Treatment · Phase 2/3 · Merck Sharp & Dohme LLC

  FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0801), Bogotá · Fundacion Valle del Lili ( Site 0802), Cali · Hospital Pablo Tobon Uribe ( Site 0804), Medellín · Instituto Médico de Alta Tecnologia S.A.S ( Site 0803), Montería · Oncologos del Occidente ( Site 0800), Pereira

  Registry updated 2026-11-03

• NCT06395103

  Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC

  Clinica de la Costa S.A.S.-Clinical Research Oncology & Hematology -Pediatric ( Site 1924), Barranquilla · Hospital Pablo Tobon Uribe ( Site 1923), Medellín · IMAT S.A.S ( Site 1921), Montería

  Registry updated 2026-10-30

• NCT06717347

  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Hospital Universitario San Ignacio ( Site 0607), Bogotá · Fundación Valle del Lili ( Site 0602), Cali · Hospital Pablo Tobon Uribe ( Site 0604), Medellín · IMAT S.A.S ( Site 0603), Montería · Oncologos del Occidente ( Site 0601), Pereira

  Registry updated 2026-10-21

All Diffuse large B-cell lymphoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error